Float Short %

7.55

Margin Of Safety %

-27

Put/Call OI Ratio

0.41

EPS Next Q Diff

-0.62

EPS Last/This Y

0.05

EPS This/Next Y

0.32

Price

40.39

Target Price

54.5

Analyst Recom

1.25

Performance Q

21.87

Relative Volume

1.7

Beta

1.25

Ticker: VCEL

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-09	VCEL	38.34	0.28	2.00	683
2025-12-10	VCEL	37.88	0.28	2.00	684
2025-12-11	VCEL	37.4	0.29	0.67	685
2025-12-12	VCEL	36.53	0.29	0.29	685
2025-12-15	VCEL	36.49	0.28	0.00	690
2025-12-16	VCEL	35.49	0.28	999.99	691
2025-12-17	VCEL	36.41	0.29	0.00	692
2025-12-18	VCEL	36.19	0.27	7.00	722
2025-12-19	VCEL	36.08	0.28	0.00	727
2025-12-22	VCEL	37.39	0.26	0.18	665
2025-12-23	VCEL	37.58	0.26	0.00	676
2025-12-26	VCEL	37.65	0.25	589.20	680
2025-12-29	VCEL	37.57	0.50	0.00	812
2025-12-30	VCEL	36.76	0.42	0.00	911
2025-12-31	VCEL	36.02	0.42	0.00	912
2026-01-02	VCEL	35.56	0.42	0.00	912
2026-01-05	VCEL	37.08	0.42	0.00	915
2026-01-06	VCEL	39.32	0.42	0.00	915
2026-01-07	VCEL	40.59	0.41	0.00	918
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-09	VCEL	38.38	1.6	-	0.26
2025-12-10	VCEL	37.67	1.6	-	0.26
2025-12-11	VCEL	37.37	1.6	-	0.26
2025-12-12	VCEL	36.53	1.6	-	0.26
2025-12-15	VCEL	36.49	1.6	-	0.26
2025-12-16	VCEL	36.49	1.6	-	0.26
2025-12-17	VCEL	36.38	1.6	-	0.26
2025-12-18	VCEL	36.17	1.6	-	0.26
2025-12-19	VCEL	36.04	1.6	-	0.26
2025-12-22	VCEL	37.70	1.6	-	0.26
2025-12-23	VCEL	37.29	1.6	-	0.26
2025-12-26	VCEL	37.69	1.6	-	0.26
2025-12-29	VCEL	37.56	1.6	-	0.26
2025-12-30	VCEL	36.74	1.6	-	0.26
2025-12-31	VCEL	35.99	1.6	-	0.26
2026-01-02	VCEL	35.63	1.6	-	0.26
2026-01-05	VCEL	37.01	1.6	-	0.26
2026-01-06	VCEL	39.30	1.6	-	0.26
2026-01-07	VCEL	40.39	1.6	-	0.26
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-09	VCEL	-6.93	-4.38	9.00
2025-12-10	VCEL	-6.93	-4.38	8.39
2025-12-11	VCEL	-6.93	-4.38	8.39
2025-12-12	VCEL	-6.99	-4.38	8.39
2025-12-15	VCEL	-6.99	-4.35	8.39
2025-12-16	VCEL	-6.99	-4.35	8.39
2025-12-17	VCEL	-6.99	-4.35	8.39
2025-12-18	VCEL	-6.99	-4.35	8.39
2025-12-19	VCEL	-6.99	-4.35	8.39
2025-12-22	VCEL	-6.99	-4.31	8.39
2025-12-23	VCEL	-6.99	-4.31	8.39
2025-12-26	VCEL	-6.99	-4.31	7.55
2025-12-29	VCEL	-6.99	-4.37	7.55
2025-12-30	VCEL	-6.99	-4.37	7.55
2025-12-31	VCEL	-6.99	-4.37	7.55
2026-01-02	VCEL	-6.99	-4.37	7.55
2026-01-05	VCEL	-6.99	-4.38	7.55
2026-01-06	VCEL	-6.99	-4.38	7.55
2026-01-07	VCEL	-6.99	-4.38	7.55
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

0.54

Avg. EPS Est. Current Quarter

0.39

Avg. EPS Est. Next Quarter

-0.08

Insider Transactions

-6.99

Institutional Transactions

-4.38

Beta

1.25

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

29.62

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

41.4

Max Drawdown 5-Year %

-74

Target Price

54.5

P/E

167.57

Forward P/E

70.75

PEG

1.05

P/S

7.89

P/B

6.34

P/Free Cash Flow

100.13

EPS

0.24

Average EPS Est. Cur. Y

0.26

EPS Next Y. (Est.)

0.58

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

5.06

Relative Volume

1.7

Return on Equity vs Sector %

-23

Return on Equity vs Industry %

-7.9

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Vericel Corporation

Sector: Healthcare

Industry: Biotechnology

Employees: 357

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

stock quote shares VCEL – Vericel Corporation Stock Price stock today

news today VCEL – Vericel Corporation stock forecast ,stock prediction 2023 2024 2025

marketwatch VCEL – Vericel Corporation yahoo finance google finance

stock history VCEL – Vericel Corporation invest stock market

stock prices VCEL premarket after hours

ticker VCEL fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: VCEL

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y